Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 376-386 |
| Number of pages | 11 |
| Journal | Allergy and Asthma Proceedings |
| Volume | 37 |
| Issue number | 5 |
| Early online date | 12 Aug 2016 |
| DOIs | |
| Publication status | Published - 1 Sep 2016 |
| Event | Meeting of the European-Academy-of-Allergy-and-Clinical-Immunology - Vienna, Austria Duration: 11 Jun 2016 → 15 Jun 2016 |
Fingerprint
Cite this
MP-AzeFlu provides rapid and effective allergic rhinitis control in real life : A pan-European study. / Klimek, Ludger; Bachert, Claus; Stjarne, Par; Dollner, Ralph; Larsen, Petter; Haahr, Peter; Agache, Ioana; Scadding, Glenis; Price, David.
In: Allergy and Asthma Proceedings, Vol. 37, No. 5, 01.09.2016, p. 376-386.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MP-AzeFlu provides rapid and effective allergic rhinitis control in real life
T2 - A pan-European study
AU - Klimek, Ludger
AU - Bachert, Claus
AU - Stjarne, Par
AU - Dollner, Ralph
AU - Larsen, Petter
AU - Haahr, Peter
AU - Agache, Ioana
AU - Scadding, Glenis
AU - Price, David
N1 - ACKNOWLEDGMENTS We thank Ruth Murray, Ph.D., for assistance with drafting, editing, and reviewing this manuscript. Funding was provided by Meda, Solna, Sweden L. Klimek has received grants, honorariums, and consulting fees from Meda and Solna. The authors have no conflicts of interest to declare pertaining to this article
PY - 2016/9/1
Y1 - 2016/9/1
N2 - Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3% of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9% of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.
AB - Background: The European Union has prioritized allergic rhinitis (AR) control. Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma has endorsed the visual analog scale (VAS) as the AR control language and incorporated it into a new AR treatment algorithm. Concurrently, the Respiratory Effectiveness Group and the European Academy of Allergy and Clinical Immunology are striving to improve the quality of published real-life AR research. Our aim was to assess the effectiveness of MP-AzeFlu by using a VAS in a well-designed, real-life, pan-European study. Methods: A total of 2988 patients (aged ≥ 12 years) with Allergic Rhinitis and its Impact on Asthma defined moderate-to-severe AR from Germany, Sweden, Romania, United Kingdom, Denmark, and Norway were included. Patients (except from the United Kingdom) assessed symptom severity by using a VAS from 0 mm (not at all bothersome) to 100 mm (very bothersome) on days 0, 1, 3, 7, and the last visit (∼day 14) in the morning before MP-AzeFlu use. Patients' perceived level of disease control was assessed on day 3. A VAS score cutoff on day 3 for “well controlled” was determined, and the proportion of patients who achieved this response was calculated. Results: MP-AzeFlu was associated with a mean VAS score reduction from 73.7 mm at baseline to 23.4 mm by the last visit. This reduction was significant (p < 0.001) compared with baseline from day 1 and sustained until the last day of the study. By day 3, 50.3% of patients considered their symptoms well controlled; 18.2, 40.0, 66.6, and 75.9% of the patients achieved the ≤38 mm well-controlled VAS score cutoff on days 1, 3, 7 and the last day, respectively. The results were consistent across countries, age, phenotype, and severity. Conclusion: MP-AzeFlu provided effective and rapid symptom control in a real-life pan-European setting and aligned with the European Union, Contre les Maladies Chronique pour un Vieillissement Actif Allergic Rhinitis and its Impact on Asthma, the Respiratory Effectiveness Group, and the European Academy of Allergy and Clinical Immunology objectives, supporting MP-AzeFlu as the drug of choice for the treatment of moderate-to-severe AR.
U2 - 10.2500/aap.2016.37.3979
DO - 10.2500/aap.2016.37.3979
M3 - Article
VL - 37
SP - 376
EP - 386
JO - Allergy and Asthma Proceedings
JF - Allergy and Asthma Proceedings
SN - 1088-5412
IS - 5
ER -